Form 4/A for FTH Faeth Therapeutics, Inc.
Accepted 2023-03-07 00:00:00 ET · period of report 2022-06-10 · accession 0001567619-23-004608 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2023-03-07 | 2022-06-10 | FTH | Cambrian BioPharma Inc | 10% | A - Grant | $0.00 | +4,466 | 5.24M | +0.1% | $0 |
| DA | 2023-03-07 | 2022-06-10 | FTH | Cambrian BioPharma Inc | 10% | A - Grant | $0.00 | +14.6K | 14.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Restricted Stock Unit Grant | 2022-06-10 | A | A | 4,466 | $0.00 | 5,235,956 | D | — | — | (F1) These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date. (F4) Amendment filed solely to correct the number of shares owned. (F2) These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |
| 2 | Derivative | Stock Option (right to buy) | 2022-06-10 | A | A | 14,550 | $0.00 | 14,550 | D | $2.05 · — to 2032-06-09 | 14,550 Common Stock | (F2) These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. (F3) The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date. |